2 - TI Pharma

REFERENCES
1. McMahon M, Gerich j, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes
Metab Rev. 1988;4(1):17-30.
2. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids.
Pharmacol Ther. 2002;96(2):23-43.
3. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson jP, Besser GM, Grossman AB, Reznek
RH. Computed tomography assessment of fat distribution in male and female patients with Cushing’s
syndrome. Eur j Endocrinol. 2003;149(6):561-7.
4. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson jP, Besser GM, Grossman AB, Reznek
RH. Hepatic steatosis in Cushing’s syndrome: a radiological assessment using computed tomography.
Eur j Endocrinol. 2003;149(6):543-8.
5. Taskinen MR, Nikkila EA, Pelkonen R, Sane T. Plasma lipoproteins, lipolytic enzymes, and very
low density lipoprotein triglyceride turnover in Cushing’s syndrome. J Clin Endocrinol Metab.
1983;57(3):619-26.
6. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic
syndrome. Endocr Rev. 2000;21(6):697-738.
7. Khaleeli AA, Edwards RH, Gohil K, McPhail G, Rennie Mj, Round j, Ross Ej. Corticosteroid myopathy:
a clinical and pathological study. Clin Endocrinol (Oxf). 1983;18(2):155-66.
8. Lambillotte C, Gilon P, Henquin jC. Direct glucocorticoid inhibition of insulin secretion. An in vitro
study of dexamethasone effects in mouse islets. j Clin Invest. 1997;99(3):414-23.
9. Larsson H, Ahren B. Insulin resistant subjects lack islet adaptation to short-term dexamethasoneinduced
reduction in insulin sensitivity. Diabetologia. 1999;42(8):936-43.
10. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet.
2005;366(9491):1059-62.
11. Reynolds RM, Walker BR, Syddall HE, Whorwood CB, Wood Pj, Phillips DI. Elevated plasma cortisol
in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture. j
Clin Endocrinol Metab. 2001;86(3):1149-53.
12. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific
amplifier of glucocorticoid action. Endocrinology. 2001;142(4):1371-6.
13. Witchel SF, DeFranco DB. Mechanisms of disease: regulation of glucocorticoid and receptor levelsimpact
on the metabolic syndrome. Nat Clin Pract Endocrinol Metab. 2006;2(11):621-31.
14. Seckl jR. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr Opin
Pharmacol. 2004;4(6):597-602.
15. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid
inactivation protects against diet-induced obesity. Diabetes. 2005;54(4):1023-31.
41
2
Chapter 2